Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045146 | 1.00 | PTAFR (0.46) | PTAFRROCK2ROCK1FYNEPHX2 | |
| SCHEMBL29411462 | 0.85 | KDM4E (0.49) | PTAFRROCK2ROCK1FYNNPC1 | |
| SCHEMBL21045432 | 0.85 | KDM4E (0.49) | PTAFRROCK2ROCK1FYNNPC1 | |
| SCHEMBL21045141 | 0.82 | EPHX2 (0.53) | PTAFREPHX2NPC1RAB9AKMT2A | |
| SCHEMBL29411581 | 0.82 | EPHX2 (0.53) | PTAFREPHX2NPC1RAB9AKMT2A | |
| SCHEMBL21045144 | 0.81 | HDAC3 (0.47) | FYNNPC1RAB9AHIF1ANAMPT | |
| SCHEMBL29411494 | 0.81 | HDAC3 (0.47) | FYNNPC1RAB9AHIF1ANAMPT | |
| SCHEMBL21045132 | 0.80 | MAPT (0.52) | NPC1RAB9AKMT2APOLB | |
| SCHEMBL21045267 | 0.80 | DHODH (0.48) | PTAFRFYNKMT2AHIF1A | |
| SCHEMBL29411570 | 0.80 | MAPT (0.52) | NPC1RAB9AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188035-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE LLC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12247010-B2 | Tubulin inhibitors | LIN BIOSCIENCE INC. (TW) | 2025-03-11 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PTAFR 2124/4885ROCK2 344/4885ROCK1 277/4885 |
| US-12247010-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | PTAFR 2124/4885ROCK2 344/4885ROCK1 277/4885 |
| US-20250188035-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PTAFR 2124/4885ROCK2 344/4885ROCK1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.